Haiyan Jiang

Summary

Affiliation: Bayer HealthCare
Country: USA

Publications

  1. pmc Effects of transient immunosuppression on adenoassociated, virus-mediated, liver-directed gene transfer in rhesus macaques and implications for human gene therapy
    Haiyan Jiang
    Bayer HealthCare Pharmaceuticals, 800 Dwight Way, Berkeley, CA 94710, USA
    Blood 108:3321-8. 2006
  2. ncbi Multiyear therapeutic benefit of AAV serotypes 2, 6, and 8 delivering factor VIII to hemophilia A mice and dogs
    Haiyan Jiang
    Avigen, Almeda, CA, USA
    Blood 108:107-15. 2006
  3. ncbi Evidence of multiyear factor IX expression by AAV-mediated gene transfer to skeletal muscle in an individual with severe hemophilia B
    Haiyan Jiang
    Avigen, Inc, Alameda, CA 94502, USA
    Mol Ther 14:452-5. 2006
  4. ncbi Human immunoglobulin inhibits liver transduction by AAV vectors at low AAV2 neutralizing titers in SCID mice
    Ciaran D Scallan
    Avgen, Alameda, CA, USA
    Blood 107:1810-7. 2006
  5. ncbi Phenotypic correction of a mouse model of hemophilia A using AAV2 vectors encoding the heavy and light chains of FVIII
    Ciaran D Scallan
    Avigen, Inc, 1201 Harbor Bay Parkway, Alameda, CA 94502, USA
    Blood 102:3919-26. 2003
  6. doi Rational design of a fully active, long-acting PEGylated factor VIII for hemophilia A treatment
    Baisong Mei
    Global Biological Development, Bayer HealthCare LLC, Berkeley, CA, USA
    Blood 116:270-9. 2010
  7. pmc Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients
    Jerry S Powell
    University of California, Davis, Sacramento, CA, USA
    Blood 119:3031-7. 2012
  8. pmc Modulation of tolerance to the transgene product in a nonhuman primate model of AAV-mediated gene transfer to liver
    Federico Mingozzi
    Division of Hematology and Center for Cellular and Molecular Therapeutics, The Children s Hospital of Philadelphia, PA 19104, USA
    Blood 110:2334-41. 2007
  9. ncbi Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response
    Catherine S Manno
    The Children s Hospital of Philadelphia, 3615 Civic Center Boulevard, Philadelphia, Pennsylvania, 19104, USA
    Nat Med 12:342-7. 2006
  10. ncbi Sustained phenotypic correction of canine hemophilia A using an adeno-associated viral vector
    Ciaran D Scallan
    Avigen, Inc, 1201 Harbor Bay Parkway, Alameda, CA 94502
    Blood 102:2031-7. 2003

Collaborators

Detail Information

Publications12

  1. pmc Effects of transient immunosuppression on adenoassociated, virus-mediated, liver-directed gene transfer in rhesus macaques and implications for human gene therapy
    Haiyan Jiang
    Bayer HealthCare Pharmaceuticals, 800 Dwight Way, Berkeley, CA 94710, USA
    Blood 108:3321-8. 2006
    ..These findings enable a clinical study to assess the effects of immunomodulation on long-term FIX expression in patients with hemophilia B...
  2. ncbi Multiyear therapeutic benefit of AAV serotypes 2, 6, and 8 delivering factor VIII to hemophilia A mice and dogs
    Haiyan Jiang
    Avigen, Almeda, CA, USA
    Blood 108:107-15. 2006
    ..In summary, this is the first report demonstrating multiyear therapeutic efficacy and safety of multiple AAV-cFVIII vectors in hemophilia A dogs and provides the basis for human clinical studies...
  3. ncbi Evidence of multiyear factor IX expression by AAV-mediated gene transfer to skeletal muscle in an individual with severe hemophilia B
    Haiyan Jiang
    Avigen, Inc, Alameda, CA 94502, USA
    Mol Ther 14:452-5. 2006
    ..These results demonstrate, for the first time, multiyear FIX expression by AAV2 vector in humans and suggest that improved muscle delivery provides effective treatment for protein deficiencies or muscle-specific diseases...
  4. ncbi Human immunoglobulin inhibits liver transduction by AAV vectors at low AAV2 neutralizing titers in SCID mice
    Ciaran D Scallan
    Avgen, Alameda, CA, USA
    Blood 107:1810-7. 2006
    ..Therefore, novel nonprimate AAV vectors or compartmentalized delivery may offer more consistent therapeutic effects in the presence of pre-existing AAV neutralizing antibodies...
  5. ncbi Phenotypic correction of a mouse model of hemophilia A using AAV2 vectors encoding the heavy and light chains of FVIII
    Ciaran D Scallan
    Avigen, Inc, 1201 Harbor Bay Parkway, Alameda, CA 94502, USA
    Blood 102:3919-26. 2003
    ..This strategy may potentially be useful for other large therapeutic proteins that contain functionally distinct domains...
  6. doi Rational design of a fully active, long-acting PEGylated factor VIII for hemophilia A treatment
    Baisong Mei
    Global Biological Development, Bayer HealthCare LLC, Berkeley, CA, USA
    Blood 116:270-9. 2010
    ..In summary site-specifically PEGylated FVIII has the potential to be a long-acting prophylactic treatment while being fully efficacious for on-demand treatment for patients with hemophilia A...
  7. pmc Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients
    Jerry S Powell
    University of California, Davis, Sacramento, CA, USA
    Blood 119:3031-7. 2012
    ..Thus, rFVIIIFc may offer a viable therapeutic approach to achieve prolonged hemostatic protection and less frequent dosing in patients with hemophilia A. This trial was registered at www.clinicaltrials.gov as NCT01027377...
  8. pmc Modulation of tolerance to the transgene product in a nonhuman primate model of AAV-mediated gene transfer to liver
    Federico Mingozzi
    Division of Hematology and Center for Cellular and Molecular Therapeutics, The Children s Hospital of Philadelphia, PA 19104, USA
    Blood 110:2334-41. 2007
    ....
  9. ncbi Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response
    Catherine S Manno
    The Children s Hospital of Philadelphia, 3615 Civic Center Boulevard, Philadelphia, Pennsylvania, 19104, USA
    Nat Med 12:342-7. 2006
    ..We conclude that rAAV-2 vectors can transduce human hepatocytes in vivo to result in therapeutically relevant levels of F.IX, but that future studies in humans may require immunomodulation to achieve long-term expression...
  10. ncbi Sustained phenotypic correction of canine hemophilia A using an adeno-associated viral vector
    Ciaran D Scallan
    Avigen, Inc, 1201 Harbor Bay Parkway, Alameda, CA 94502
    Blood 102:2031-7. 2003
    ..These data support the use of AAV2 vectors in human clinical trials to treat hemophilia A patients...
  11. ncbi CD8(+) T-cell responses to adeno-associated virus capsid in humans
    Federico Mingozzi
    The Children s Hospital of Philadelphia, 3615 Civic Center Boulevard, Philadelphia, Pennsylvania 19104, USA
    Nat Med 13:419-22. 2007
    ..In addition, we show that AAV-2 induced human T cells proliferate upon exposure to alternate AAV serotypes, indicating that other serotypes are unlikely to evade capsid-specific immune responses...
  12. pmc The enhancing effects of the light chain on heavy chain secretion in split delivery of factor VIII gene
    Lingxia Chen
    Department of Pediatrics, University of Pennsylvania Medical Center and The Children s Hospital of Philadelphia, Philadelphia, Pennsylvania 19104, USA
    Mol Ther 15:1856-62. 2007
    ..In sum, enhancing the secretion of the FVIII HC polypeptide may require the proper association of the FVIII LC polypeptide in cis or in trans. These results may be helpful in designing new strategies to improve FVIII gene delivery...